

# Assess the Safety and Tolerability of SNS851 in Healthy Participants

NCT07417124

---

Status	RECRUITING
Phase	Phase 1
Sponsor	Oneness Biotech Co., Ltd.
Enrollment	52 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Able to provide written informed consent. Willing, committed, and able to return for all clinic visits and complete all protocol specified procedures.
- Healthy male or female, aged between 18 and 55 years, inclusive at screening.
- Body mass index (BMI) of greater than or equal to 18 kg/m<sup>2</sup> and lesser than or equal to 32 kg/m<sup>2</sup> at Screening.
- Negative human immunodeficiency virus, viral hepatitis B and C serology at Screening.
- No major changes in diet, alcohol intake, or physical activity within 4 weeks before dosing and no intention to modify during confinement or follow-up.

... and 3 more (see full listing online)

### Exclusion (21)

- Weight loss of more than 10% within the last 3 months prior to screening.
- Has any clinical safety laboratory result considered clinically significant by the Investigator (or designee)
- In the opinion of the PI (or designee), has evidence of other forms of known chronic liver disease
- Participants with history or pre-existing renal disease
- Relevant history (in the opinion of the PI or designee) of cardiac arrhythmias including long QT syndrome, sudden cardiac death, or Torsades de Pointes and/or syncope and/or clinically significant cardiovascular event or history of uncontrolled hypertension or orthostatic hypotension within the last 6 months prior to the Screening Visit.

... and 16 more (see full listing online)

## Locations (1 total)

---

Veritus Research, Melbourne, Australia